Evidence map›Paper›PMID 32037154›Full record

ArticleThe Journal of pediatrics2020

Acute Kidney Injury During Treatment with Intravenous Acyclovir for Suspected or Confirmed Neonatal Herpes Simplex Virus Infection.

Kevin J Downes, Craig L K Boge, Elande Baro, Gerold T Wharton, Kellie M Liston, Brittany L Haltzman, Hannah M Emerson, Edwin Doe, Rosanna Fulchiero, Van Tran and 10 more

Open access · greenAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of pediatrics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Observational
  4. Review
  5. Clinical Review of Risk of Nephrotoxicity with Acyclovir Use for Treatment of Herpes Simplex Virus Infections in Neonates and Children.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2023
    Article
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 5 institutions in 1 country.

Kevin J DownesDivision of Infectious Disease, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA; Center for Pediatric Clinical Effectiveness, Children's Hospital of Philadelphia, Research Institute, Philadelphia, PA; Department of Pediatrics, Perelman School of Medicine of the University of Pennsylvania, Philadelphia, PA. Electronic address: downeskj@email.chop.edu.
Craig L K BogeCenter for Pediatric Clinical Effectiveness, Children's Hospital of Philadelphia, Research Institute, Philadelphia, PA.
Elande BaroOffice of Biostatistics, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD.
Gerold T WhartonOffice of Pediatric Therapeutics, US Food and Drug Administration, Silver Spring, MD.
Kellie M ListonCenter for Pediatric Clinical Effectiveness, Children's Hospital of Philadelphia, Research Institute, Philadelphia, PA.
Brittany L HaltzmanCenter for Pediatric Clinical Effectiveness, Children's Hospital of Philadelphia, Research Institute, Philadelphia, PA.
Hannah M EmersonCenter for Pediatric Clinical Effectiveness, Children's Hospital of Philadelphia, Research Institute, Philadelphia, PA.
Edwin DoeNeonatal Intensive Care, Inova Children's Hospital, Falls Church, VA.
Rosanna FulchieroNeonatal Intensive Care, Inova Children's Hospital, Falls Church, VA.
Van TranNeonatal Intensive Care, Inova Children's Hospital, Falls Church, VA.
Lilly YenDepartment of Pharmacy, Children's Hospital Los Angeles, Los Angeles, CA.
Phuong LieuDepartment of Pharmacy, Children's Hospital Los Angeles, Los Angeles, CA.
Sara L Van DriestDepartment of Pediatrics, Vanderbilt University Medical Center, Nashville, TN.
Alison G GrissoDepartment of Pharmaceutical Services, Vanderbilt University Medical Center, Nashville, TN.
Ida T AkaDepartment of Pediatrics, Vanderbilt University Medical Center, Nashville, TN.
Jennifer HaleDepartment of Pharmaceutical Services, Vanderbilt University Medical Center, Nashville, TN.
Jessica GillonDepartment of Pharmaceutical Services, Vanderbilt University Medical Center, Nashville, TN.
Julie S PingelDepartment of Pharmaceutical Services, Vanderbilt University Medical Center, Nashville, TN.
Susan E CoffinDivision of Infectious Disease, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA; Center for Pediatric Clinical Effectiveness, Children's Hospital of Philadelphia, Research Institute, Philadelphia, PA; Department of Pediatrics, Perelman School of Medicine of the University of Pennsylvania, Philadelphia, PA.
Ann W McMahonOffice of Pediatric Therapeutics, US Food and Drug Administration, Silver Spring, MD.
Children's Hospital of Philadelphia · USVanderbilt University Medical Center · USInova Children's Hospital · USUnited States Food and Drug Administration · USChildren's Hospital of Los Angeles · US

Funding

Optimizing Vancomycin Therapy in ChildrenK23HD091365 · NICHD · CHILDREN'S HOSP OF PHILADELPHIA · PI DOWNES, KEVIN JAMES · 2018 to 2022
$747k
NICHD NIH HHS K23 HD091365
6 · The paper itself

Abstract

objectiveTo describe the epidemiology of and risk factors associated with acute kidney injury (AKI) during acyclovir treatment in neonates and infants. STUDY

designWe conducted a multicenter (n = 4), retrospective cohort study of all hospitalized infants age <60 days treated with intravenous acyclovir (≥1 dose) for suspected or confirmed neonatal herpes simplex virus disease from January 2011 to December 2015. Infants with serum creatinine measured both before acyclovir (baseline) and during treatment were included. We classified AKI based on changes in creatinine according to published neonatal AKI criteria and performed Cox regression analysis to evaluate risk factors for AKI during acyclovir treatment.

resultsWe included 1017 infants. The majority received short courses of acyclovir (median, 5 doses). Fifty-seven infants (5.6%) developed AKI during acyclovir treatment, with an incidence rate of AKI at 11.6 per 1000 acyclovir days. Cox regression analysis identified having confirmed herpes simplex virus disease (OR, 4.35; P = .002), receipt of ≥2 concomitant nephrotoxic medications (OR, 3.07; P = .004), receipt of mechanical ventilation (OR, 5.97; P = .001), and admission to an intensive care unit (OR, 6.02; P = .006) as risk factors for AKI during acyclovir treatment.

conclusionsAmong our cohort of infants exposed to acyclovir, the rate of AKI was low. Sicker infants and those exposed to additional nephrotoxic medications seem to be at greater risk for acyclovir-induced toxicity and warrant closer monitoring.

Indexed as

Acute Kidney InjuryAcyclovirAdministration, IntravenousAdolescentChildChild, PreschoolCohort StudiesFemaleHerpes SimplexHumansInfant, NewbornMalePregnancy Complications, InfectiousRetrospective StudiesRisk FactorsAcyclovirAKIepidemiologyHSV diseaseHSV infectioninfantneonatenephrotoxicity

Identifiers

PMID32037154
PMCPMC7096264
OpenAlexW3005170217

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.